Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensipar Treatment Algorithm for SHPT (START)
NCT00132431Phase 4Completed
- Sponsor
- Amgen
- Start
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Proportion of subjects with mean bio-intact parathyroid hormone (biPTH) >= 80 pg/mL and <= 160 pg/mL. Started Jul 2004; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00132431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132431.